Breaking News

Bayer, Aronora in Preclinical Mfg. Pact

Will manufacture AB-022 for the treatment of cardiovascular diseases

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Bayer HealthCare and Aronora, Inc. have entered a strategic alliance to manufacture Aronora’s AB-022 compound for the treatment of cardiovascular diseases. As a tenant of the U.S. CoLaborator, Bayer’s life sciences incubator facility in San Francisco, Aronora, will partner with Bayer HealthCare’s Global Biologics Development group in Berkeley for the preclinical manufacture of AB-022.    “We have established a close, trusted relationship with Bayer HealthCare,” said...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters